Astex terminates epigenetics collaboration with GSK

Astex Pharmaceuticals ($ASTX) says it has decided to hand over the epigenetics program SuperGen was partnered on with GlaxoSmithKline ($GSK) following its merger with the biotech company. SuperGen partnered with GSK back in 2009, but the program failed to make the cut during a pipeline review of the companies' combined assets. "The decision to transfer the Climb epigenetic program to GSK was based on our assessment of internal resources and discussions with GSK," said Harren Jhoti, president of Astex. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.